← Back to patent-cliff list
CAS 1246643-72-0
7,7-dimethyl-1-[(oxaziridine-2-sulfonyl)methyl]bicyclo[2.2.1]heptan-2-one
Codes：(VII)101438-11-a
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(2R,4R,5S)-4,10,11,11-tetramethyltricyclo[5.3.1.0(1,5)]undec-9-ene-2,5-diol→(2R,4R,5S)-4,10,11,11-tetramethyl-2-[(triethylsilyl)oxy]tricyclo[5.3.1.0(1,5)]undec-9-en-5-ol→(1R,4R,6R,9S)-9-[(tert-butyldimethylsilyl)oxy]-4,8,11,11-tetramethyl-6-[(triethylsilyl)oxy]bicyclo[5.3.1]undec-7-en-3-one→4-Pentenal→(1S,2R,3S,4R,6R,9S)-9-[(tert-butyldimethylsilyl)oxy]-4-[(1S)-1-hydroxypent-4-en-1-yl]-4,8,11,11-tetramethyl-6-[(triethylsilyl)oxy]bicyclo[5.3.1]undec-7-ene-2,3-diol→(1R,4R,6R,9S)-9-[(tert-butyldimethylsilyl)oxy]-4-[(1S)-1-hydroxypent-4-en-1-yl]-4,8,11,11-tetramethyl-6-[(triethylsilyl)oxy]bicyclo[5.3.1]undec-7-en-3-one→(1S)-1-[(1R,4R,6R,9S)-9-[(tert-butyldimethylsilyl)oxy]-4,8,11,11-tetramethyl-3-oxo-6-[(triethylsilyl)oxy]bicyclo[5.3.1]undec-7-en-4-yl]pent-4-en-1-yl propanoate→7,7-dimethyl-1-[(oxaziridine-2-sulfonyl)methyl]bicyclo[2.2.1]heptan-2-one→(1S)-1-[(1S,2R,4R,6R,9S)-9-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-4,8,11,11-tetramethyl-3-oxo-6-[(triethylsilyl)oxy]bicyclo[5.3.1]undec-7-en-4-yl]pent-4-en-1-yl propanoate→(1S,2R,3S,7S,8R,10R,13S)-7-(but-3-en-1-yl)-13-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8,12,15,15-tetramethyl-10-[(triethylsilyl)oxy]-4,6-dioxatricyclo[9.3.1.0(3,8)]pentadec-11-en-5-one→(1S,3S,7S,8R,10R,13S)-7-(but-3-en-1-yl)-13-[(tert-butyldimethylsilyl)oxy]-8,12,15,15-tetramethyl-10-[(triethylsilyl)oxy]-4,6-dioxatricyclo[9.3.1.0(3,8)]pentadec-11-ene-2,5-dione→(1S,3S,6S,7R,9R,12S)-6-(but-3-en-1-yl)-12-[(tert-butyldimethylsilyl)oxy]-3-hydroxy-7,11,14,14-tetramethyl-9-[(triethylsilyl)oxy]-5-oxatricyclo[8.3.1.0(3,7)]tetradec-10-ene-2,4-dione→(1S,6S,7S,9R,12S)-6-(but-3-en-1-yl)-12-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-7,11,14,14-tetramethyl-9-[(triethylsilyl)oxy]-5-oxatricyclo[8.3.1.0(3,7)]tetradeca-2,10-dien-4-one→(1S,3R,6S,7S,9R,12S)-6-(but-3-en-1-yl)-12-[(tert-butyldimethylsilyl)oxy]-7,11,14,14-tetramethyl-9-[(triethylsilyl)oxy]-5-oxatricyclo[8.3.1.0(3,7)]tetradec-10-ene-2,4-dione→(1S,3S,6S,7S,9R,12S)-6-(but-3-en-1-yl)-12-[(tert-butyldimethylsilyl)oxy]-7,11,14,14-tetramethyl-9-[(triethylsilyl)oxy]-5-oxatricyclo[8.3.1.0(3,7)]tetradec-10-ene-2,4-dione→(1S,3R,6S,7S,9R,12S)-6-(but-3-en-1-yl)-12-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-7,11,14,14-tetramethyl-9-[(triethylsilyl)oxy]-5-oxatricyclo[8.3.1.0(3,7)]tetradec-10-ene-2,4-dione→(1S,3S,6S,7S,9R,12S)-6-(but-3-en-1-yl)-12-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-7,11,14,14-tetramethyl-9-[(triethylsilyl)oxy]-5-oxatricyclo[8.3.1.0(3,7)]tetradec-10-ene-2,4-dione→(1S,2S,3R,6S,7S,9R,12S)-6-(but-3-en-1-yl)-12-[(tert-butyldimethylsilyl)oxy]-1,2-dihydroxy-7,11,14,14-tetramethyl-9-[(triethylsilyl)oxy]-5-oxatricyclo[8.3.1.0(3,7)]tetradec-10-en-4-one→(1S,5S,6R,9S,10S,12R,15S)-9-(but-3-en-1-yl)-15-[(tert-butyldimethylsilyl)oxy]-10,14,17,17-tetramethyl-12-[(triethylsilyl)oxy]-2,4,8-trioxatetracyclo[11.3.1.0(1,5).0(6,10)]heptadec-13-ene-3,7-dione
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.